IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing. The results were reported at the recent American Society of Clinical Oncology (ASCO) 2014 Breast Cancer Symposium (#BCS14), held Sept. 4-6 in San Francisco.
The prospective observational study of 515 patients showed that the 80-gene BluePrint test reclassified 22% of tumors overall – meaning that it more accurately identified breast cancer subtypes than did the IHC-FISH tests. Based on these results, researchers concluded that the BluePrint assay may be superior to IHC-FISH testing for guiding physicians’ decisions about how to treat their patients’ early-stage breast cancers before surgery.
Help employers find you! Check out all the jobs and post your resume.
